Stage 0 Chronic Lymphocytic Leukemia: Clinical Trials

2 trials for Stage 0 Chronic Lymphocytic Leukemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed. 2 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 12Completed 2
Phase 22Completed 2

Follow Stage 0 Chronic Lymphocytic Leukemia: new trials by email Literature Review of Stage 0 Chronic Lymphocytic Leukemia trials Research Report on Stage 0 Chronic Lymphocytic Leukemia

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
lenalidomide, etoposide, prednisone - Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia
Phase 1 / Phase 2CompletedUniversity of Chicago552014-07-292026-03-11
Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia
alemtuzumab, rituximab, PGG beta-glucan - B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia
Phase 1 / Phase 2CompletedMayo Clinic222011-01-012020-06-23

Narrower conditions

Leukemia, Lymphocytic, Chronic, B-Cell (2)  ·  Hodgkin Disease (1)  ·  Intraocular Lymphoma (1)  ·  Lymphoma, B-Cell, Marginal Zone (1)  ·  Lymphoma, Follicular (1)  ·  Lymphoma, Large B-Cell, Diffuse (1)  ·  Lymphoma, Large-Cell, Immunoblastic (1)  ·  Lymphoma, Mantle-Cell (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Waldenstrom Macroglobulinemia (1)

Broader conditions

Chronic Disease (2)  ·  Disease Attributes (2)  ·  Hematologic Diseases (2)  ·  Hemic and Lymphatic Diseases (2)  ·  Immune System Diseases (2)  ·  Immunoproliferative Disorders (2)  ·  Leukemia (2)  ·  Leukemia, B-Cell (2)  ·  Leukemia, Lymphoid (2)  ·  Lymphatic Diseases (2)  ·  Lymphoproliferative Disorders (2)  ·  Neoplasms (2)  ·  Neoplasms by Histologic Type (2)  ·  Pathologic Processes (2)  ·  Pathological Conditions, Signs and Symptoms (2)

Interventions

Rituximab (2)  ·  Alemtuzumab (1)  ·  Amplified Fragment Length Polymorphism Analysis (1)  ·  Cyclophosphamide (1)  ·  Doxorubicin (1)  ·  Etoposide (1)  ·  Flow Cytometry (1)  ·  In Situ Hybridization, Fluorescence (1)  ·  Lenalidomide (1)  ·  Polymerase Chain Reaction (1)  ·  Prednisone (1)  ·  Vincristine (1)

Sponsors

Mayo Clinic (1)  ·  University of Chicago (1)

Countries

United States (2)

Top investigators

Sonali Smith (1)  ·  Steven Ansell, M.D. (1)

Results publications

PMID 40720747

NIH funding

P30CA014599 (1)